Skip to main content
Premium Trial:

Request an Annual Quote

iCubate Bloodstream Infection Assay Cleared by FDA

NEW YORK – iCubate said late on Friday that the US Food and Drug Administration cleared the company's assay for detecting and identifying potentially pathogenic gram-negative bacteria associated with bloodstream infection and subsequent sepsis. 

The iC-GN Assay uses multiplex PCR to detect target DNA and identify gram-negative organisms associated with gram-negative bacteremia such as Acinetobacter baumannii complex, Escherichia coli, and Klebsiella pneumonia. It also identifies three antibiotic-resistance markers, including KPC and NDM, which have been associated with carbapenem resistance.  

The test was CE marked in late June.

According to Huntsville, Alabama-based iCubate, this most recent clearance along with the previously cleared iC-GPC Assay completes the firm's comprehensive bloodstream infection detection solution for US clinical labs. 

"With the ability to provide reliable and cost-effective assays for detecting BSI to laboratories of any size, we are confident that iCubate will add value for health care providers to improve patient outcomes," iCubate CEO Carter Wells said in a statement. 

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.